Esperion
The Lipid Management Company

Esperion Therapeutics, Inc.
Investor Relations Department
3891 Ranchero Drive
Suite 150
Ann Arbor, MI 48108
United States

Visit IR website
Sign-up for Email alerts

NASDAQ: ESPR	
Last Trade:	49.19
Trade Time:	4:00 PM ET Nov 17, 2017
Change:	-0.30 (-0.606%)
Day Range	48.50 - 49.54
52-Week Range	10.30 - 57.40
Volume	275,099

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Esperion is a late-stage pharmaceutical company passionately committed to developing and commercializing complementary, non-statin, once-daily, oral therapies to lower elevated low density lipoprotein (LDL) cholesterol for patients with hypercholesterolemia not adequately treated with current lipid-modifying therapies. Bempedoic acid, a convenient, complementary, cost-effective, once-daily, oral inhibitor of ATP Citrate Lyase (ACLi) brings a targeted mechanism of action to address patients unmet medical needs in a way that is "patient-friendly, physician-frie... (more)

Stock Performance



Press Releases [View all]

Nov 13, 2017
Esperion to Participate in Fireside Chat at the Jefferies 2017 London Healthcare Conference

Nov 9, 2017
Esperion to Participate in Fireside Chat at the Stifel 2017 Healthcare Conference

Nov 7, 2017
Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Third Quarter 2017 Financial Results

Nov 6, 2017
Esperion Announces Initiation of Pivotal Phase 3 Study for the Bempedoic Acid / Ezetimibe Combination Pill

Oct 10, 2017
Esperion to Host Analyst and Investor Day Event on October 17

Financials [View all]

Third Quarter Financial Results

Feb 22, 2017
Annual Report (10-K)

Mar 6, 2017
Proxy Statement (DEF 14A)

Nov 7, 2017
Quarterly Report (10-Q)

Aug 8, 2017
Quarterly Report (10-Q)

May 4, 2017
Quarterly Report (10-Q)